Skip to content
Study details
Enrolling now

Atorvastatin Postpartum and Reduction of Cardiovascular Risk

Ohio State University
NCT IDNCT06632379ClinicalTrials.gov data as of Apr 2026
Phase

Phase 4

Target enrollment

76

Study length

about 1.2 years

Ages

20–50

Sex

Female only

Locations

1 site in OH

About this study

This trial is testing whether atorvastatin, a medication, reduces cardiovascular risk in postpartum women with hypertensive disorders of pregnancy. Women will be randomly assigned to either atorvastatin 10mg or a placebo after breastfeeding stops for three months.

Based on ClinicalTrials.gov records.

What participants do

  • 1.Take Atorvastatin 10 mg
  • 2.Take Placebo
PhasePhase 4
DrugAtorvastatin 10 mg
Routeoral

Participation effort

Estimated from trial records. Details can vary by site.

Time + visits
Low12%
Logistics
Moderate50%

Logistics difficulty varies by site location and availability.

Trial highlights

Treatment details

Auto-extracted from trial records to preview treatments and outcomes.

Drug classes

atorvastatin (Statin; inhibits HMG-CoA reductase to lower cholesterol)

Drug routes

oral

Endpoints

Secondary: Estimated glomerular filtration rate, Fasting glucose, High-sensitivity C-reactive protein (Hs-CRP) level, Systolic blood pressure, Waist circumference

Body systems

Reproductive Health, Cardiology / Heart